Payment overview · 2025
General Payments
$851.82
41 reported records · 19 companies
Healthcare provider profile · identity verified
Dharmeshkumar Chhaganlal Patel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LITHONIA, GA · NPI 1902990336
Verified facts
What the public records show
CMS Open Payments records show Dharmeshkumar Chhaganlal Patel, M.D. received $851.82 in general payments during 2025 across 41 reported records.
GlaxoSmithKline, LLC. accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $138.12 | 16.2% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $117.57 | 13.8% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $96.70 | 11.3% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.78 | 8.3% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.96 | 5.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $42.34 | 5.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.30 | 4.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.75 | 4.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.79 | 4.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.14 | 4.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.33 | 4.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.28 | 2.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $23.18 | 2.7% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $22.95 | 2.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.56 | 2.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $18.38 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.56 | 2.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.24 | 1.7% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $6.89 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $851.82 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $114.71 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $95.83 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63.25 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $63.04 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.87 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $49.96 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $48.90 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $42.34 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.14 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.46 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.41 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $6.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 116 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 50 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 237 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
110 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 39 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
237 | 54 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1355 | 410 |
| Amlodipine Besylate | Amlodipine Besylate | 1014 | 336 |
| Metformin Hcl | Metformin Hcl | 765 | 238 |
| Omeprazole | Omeprazole | 644 | 216 |
| Losartan Potassium | Losartan Potassium | 629 | 190 |
| Fluticasone Propionate | Fluticasone Propionate | 525 | 249 |
| Lisinopril | Lisinopril | 501 | 153 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 426 | 185 |
| Levothyroxine Sodium | Levothyroxine Sodium | 384 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 346 | 95 |
| Gabapentin | Gabapentin | 330 | 167 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 309 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 307 | 109 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 281 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 257 | 90 |
| Carvedilol | Carvedilol | 256 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 76 |
| Pravastatin Sodium | Pravastatin Sodium | 249 | 67 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 241 | 112 |
| Ozempic | Semaglutide | 237 | 54 |
| Furosemide | Furosemide | 230 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 73 |
| Prednisone | Prednisone | 202 | 124 |
| Famotidine | Famotidine | 198 | 63 |
| Montelukast Sodium | Montelukast Sodium | 196 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 195 | 62 |
| Hydralazine Hcl | Hydralazine Hcl | 191 | 63 |
| Glimepiride | Glimepiride | 164 | 50 |
| Alendronate Sodium | Alendronate Sodium | 163 | 43 |
| Potassium Chloride | Potassium Chloride | 160 | 53 |
| Sertraline Hcl | Sertraline Hcl | 154 | 55 |
| Metformin Hcl Er | Metformin Hcl | 132 | 44 |
| Jardiance | Empagliflozin | 116 | 39 |
| Simvastatin | Simvastatin | 116 | 30 |
| Farxiga | Dapagliflozin Propanediol | 110 | 42 |
| Allopurinol | Allopurinol | 108 | 40 |
| Clonidine Hcl | Clonidine Hcl | 101 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 101 | 36 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 101 | 50 |
| Amoxicillin | Amoxicillin | 100 | 77 |
| Azithromycin | Azithromycin | 96 | 71 |
| Meloxicam | Meloxicam | 94 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 62 |
| Atenolol | Atenolol | 87 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 72 |
| Oxybutynin Chloride | Oxybutynin Chloride | 82 | 26 |
| Nifedipine Er | Nifedipine | 81 | 31 |
| Donepezil Hcl | Donepezil Hcl | 80 | 26 |
| Fluconazole | Fluconazole | 80 | 53 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 26 |
| Trazodone Hcl | Trazodone Hcl | 80 | 39 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 78 | 70 |
| Eliquis | Apixaban | 75 | 31 |
| Ibuprofen | Ibuprofen | 74 | 43 |
| Pregabalin | Pregabalin | 70 | 19 |
| Mounjaro | Tirzepatide | 68 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 68 | 23 |
| Nystatin | Nystatin | 67 | 39 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 58 |
| Januvia | Sitagliptin Phosphate | 64 | 18 |
| Glipizide | Glipizide | 63 | 17 |
| Naproxen | Naproxen | 63 | 49 |
| Ezetimibe | Ezetimibe | 62 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 40 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 60 | 24 |
| Colchicine | Colchicine | 58 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 24 |
| Finasteride | Finasteride | 57 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 20 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 55 | 20 |
| Meclizine Hcl | Meclizine Hcl | 53 | 32 |
| Chlorthalidone | Chlorthalidone | 51 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 14 |
| Linzess | Linaclotide | 50 | 18 |
| Novolog Flexpen | Insulin Aspart | 50 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | 14 |
| Xarelto | Rivaroxaban | 45 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 12 |
| Cromolyn Sodium | Cromolyn Sodium | 43 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 43 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 17 |
| Spironolactone | Spironolactone | 43 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 15 |
| Fenofibrate | Fenofibrate | 39 | 11 |
| Ketoconazole | Ketoconazole | 38 | 15 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Valsartan | Valsartan | 38 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 36 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 11 |
| Mirtazapine | Mirtazapine | 35 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | 12 |
| Labetalol Hcl | Labetalol Hcl | 34 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 34 | 12 |
| Tramadol Hcl | Tramadol Hcl | 33 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 12 |
| Valacyclovir | Valacyclovir Hcl | 32 | 19 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 32 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | 16 |
| Hydrocortisone | Hydrocortisone | 31 | 11 |
| Metronidazole | Metronidazole | 31 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | 12 |
| Torsemide | Torsemide | 27 | 13 |
| Cephalexin | Cephalexin | 26 | 24 |
| Ondansetron Odt | Ondansetron | 26 | 16 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | 11 |
| Mupirocin | Mupirocin | 25 | 19 |
| Lactulose | Lactulose | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Telmisartan | Telmisartan | 21 | suppressed |
| Topiramate | Topiramate | 21 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Acebutolol Hcl | Acebutolol Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Perphenazine | Perphenazine | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Ciclopirox | Ciclopirox | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Tretinoin | Tretinoin | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $851.82 · 41 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, BREZTRI, CeQur Simplicity, Cologuard Collection Kit, FREESTYLE LIBRE 3, Fluad, Flucelvax, JARDIANCE, Kerendia, LAGEVRIO, LINZESS, MOUNJARO, NEFFY, NEXLETOL, NURTEC ODT, OPSUMIT, Ozempic, PROCLAIM, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UPTRAVI, VOQUEZNA, VRAYLAR, WaveWriter Alpha Prime 16, Wegovy, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error